Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 09

514P - Immunophenotypic profile of glioblastoma microenvironment: A cohort study

Date

21 Oct 2023

Session

Poster session 09

Topics

Tumour Immunology

Tumour Site

Central Nervous System Malignancies

Presenters

Lidia Gatto

Citation

Annals of Oncology (2023) 34 (suppl_2): S391-S409. 10.1016/S0923-7534(23)01934-8

Authors

L. Gatto1, C. Agostinelli2, V. Di Nunno3, S. righi2, A. Tosoni4, F. Ambrosi5, U. Vardy6, S. Bartolini4, L. Ranieri4, S. Asioli7, E. Franceschi8

Author affiliations

  • 1 Department Of Oncology, Azienda Unità Sanitaria Locale (ausl) Bologna, Bologna, Italy, Azienda Unità Sanitaria Locale (AUSL) Bologna, Bologna, Italy, 40139 - Bologna/IT
  • 2 Department Of Medical And Surgical Sciences, University of Bologna, Bologna, Italy, 40126 - Bologna/IT
  • 3 Department Of Oncology, Azienda Unità Sanitaria Locale (AUSL) Bologna, Bologna, Italy, 40124 - Bologna/IT
  • 4 Nervous System Medical Oncology Department, Irccs Istituto Delle Scienze Neurologiche Di Bologna, 40139 Bologna, Italy, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy, 40124 - Bologna/IT
  • 5 Pathology Unit, Department Of Experimental, Diagnostic, And Specialty Medicine (dimes), University Of Bologna, University of Bologna, Bologna, Italy, 40126 - Bologna/IT
  • 6 School Of Medicine And Surgery, University Of Bologna, University of Bologna - Alma Mater Studiorum, 40126 - Bologna/IT
  • 7 Department Of Biomedical And Neuromotor Sciences (dibinem), University Of Bologna, Bologna, Italy, University of Bologna, Bologna, Italy, 40126 - Bologna/IT
  • 8 Nervous System Medical Oncology Department, Irccs Istituto Delle Scienze Neurologiche Di Bologna, 40139 Bologna, Italy, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy, 40139 - Bologna/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 514P

Background

Glioblastoma (GBM) is the most aggressive brain tumor in adults and is characterized by an immunosuppressive microenvironment. Different factors shaping its tumor microenvironment (TME) regulate tumor initiation, progression, and treatment response. The aim of this study was to characterize the TME and the expression of immunomodulatory targets in patients (pts) with GBM.

Methods

Immunohistochemistry for CD3, CD4, CD8, programed death ligand 1 (PD-L1) and programed death 1 (PD1) was performed on surgical tumor specimens from pts diagnosed with GBM, according to the CNS WHO 2021 criteria. A descriptive statistic was applied to the data set. OS and PFS were estimated through the Kaplan-Meier method and analyzed by the means of a log-rang test.

Results

We included 30 pts, with median age of 59.8 years [range 40.2-69.1 years]. All pts were treated with surgery followed by temozolomide concurrent with and adjuvant to radiotherapy. MGMT was methylated in 46.7% of pts and unmethylated in 53.3% of pts. Overall CD4+ lymphocytes, both intratumoral and perivascular, were significantly more represented than CD8+ lymphocytes in the GBM TME (p= 0.01). A lower density of CD4+ lymphocytes (<10%) was found to be a favorable prognostic factor for GBM outcome (p= 0.02). Pts with MGMT methylated and unmethylated tumors exhibited a distinct TME composition, with a significant higher number of perivascular CD8+ lymphocytes (p= 0.002), intratumoral CD8+ lymphocytes (p= 0.0024) and perivascular CD4+ lymphocytes (p=0.014) in MGMT unmethylated compared to MGMT methylated tumors. PD-L1 expression in GBM cell surface was 13.3% (n=4) and PD1 was expressed in 30% (N=9) of the GBM-infiltrating T cells, with predominantly perivascular distribution.

Conclusions

CD4+ lymphocytes lower density (<10%) correlates with improved survival. Given the small numbers of our cohort, the prognostic value of CD4+ lymphocytes density needs to be validated in large-scale studies. MGMT methylated and unmethylated tumors exhibit different immune profiles, reflecting the different biology of these tumors. The expression of PD-L1 and PD1 in GBM patients is confined to a small subpopulation.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.